Fidaxomicin Attains High Fecal Concentrations With Minimal Plasma Concentrations Following Oral Administration in Patients With Clostridium difficile Infection

Fidaxomicin has recently been approved for the treatment of Clostridium difficile infection (CDI). As part of phase III studies, plasma and fecal samples were analyzed for concentrations of fidaxomicin and its metabolite, OP-1118. Plasma samples were collected before and after dose receipt on the fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sears, Pamela, Crook, Derrick W., Louie, Thomas J., Miller, Mark A., Weiss, Karl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2012
Materias:
Supplement Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388019/
https://www.ncbi.nlm.nih.gov/pubmed/22752859
http://dx.doi.org/10.1093/cid/cis337

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388019/
https://www.ncbi.nlm.nih.gov/pubmed/22752859
http://dx.doi.org/10.1093/cid/cis337

Ejemplares similares